Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Current Deferred Revenue (2024 - 2026)

Camp4 Therapeutics' Current Deferred Revenue history spans 2 years, with the latest figure at $9.4 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 2338.18% to $9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.4 million, a 2338.18% increase, with the full-year FY2025 number at $9.4 million, up 2338.18% from a year prior.
  • Current Deferred Revenue hit $9.4 million in Q4 2025 for Camp4 Therapeutics, up from $385000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for CAMP hit a ceiling of $9.4 million in Q4 2025 and a floor of $385000.0 in Q4 2024.